Previous Close | 19.05 |
Open | 19.04 |
Bid | 18.75 x 1300 |
Ask | 19.59 x 800 |
Day's Range | 18.86 - 19.33 |
52 Week Range | 13.03 - 23.92 |
Volume | 1,000,241 |
Avg. Volume | 1,259,675 |
Market Cap | 3.029B |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.70 |
Earnings Date | Apr 27, 2021 - May 03, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.89 |
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), Alkermes' novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD's KEYTRUDA® (pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer. Under the terms of the agreement, Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021.
Does the March share price for Alkermes plc ( NASDAQ:ALKS ) reflect what it's really worth? Today, we will estimate the...